恒瑞医药(600276) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥7,426,888,299.87, representing a year-on-year increase of 12.72%[3] - Total profit for the period was ¥1,361,073,585.78, reflecting a growth of 1.94% compared to the same period last year[3] - Net profit attributable to shareholders was ¥1,301,063,153.19, up by 9.53% year-on-year[3] - Total operating revenue for the first three quarters of 2025 reached ¥23,188,081,928.77, an increase of 14.8% compared to ¥20,189,303,845.10 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was ¥5,760,235,152.02, compared to ¥4,616,330,177.46 in 2024, marking a growth of 24.7%[17] - Earnings per share for the first three quarters of 2025 were ¥0.89, an increase from ¥0.73 in the same period of 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities for the period was ¥4,809,977,038.87, a significant increase of 209.78%[3] - In the first three quarters of 2025, the net cash flow from operating activities was ¥9,110,430,290.27, a significant increase of 98.5% compared to ¥4,585,446,009.12 in the same period of 2024[20] - Cash received from the sale of goods and services reached ¥26,173,262,016.04, up 30.8% from ¥20,000,144,131.46 in the previous year[20] - The net increase in cash and cash equivalents for the period was ¥15,528,606,009.65, compared to ¥1,184,255,955.68 in the previous year, reflecting strong liquidity growth[20] - The cash and cash equivalents at the end of the period totaled ¥39,767,708,127.31, a significant rise from ¥21,455,780,225.40 at the end of the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥68,327,540,485.78, marking a 36.29% increase from the previous year[4] - Total assets as of September 30, 2025, amounted to ¥68,327,540,485.78, compared to ¥50,135,645,304.10 at the end of 2024, indicating a growth of 36.2%[14] - Total liabilities increased to ¥8,295,022,482.91 from ¥4,045,394,570.79, representing a rise of 104.5%[14] Shareholder Information - The equity attributable to shareholders reached ¥59,504,250,787.19, which is a 30.72% increase compared to the end of the previous year[4] - The company reported a total of 397,258 ordinary shareholders at the end of the reporting period[10] - The largest shareholder, Jiangsu Hengrui Medicine Group Co., Ltd., holds 1,538,184,187 shares, accounting for 23.18% of the total shares[10] - The total equity attributable to shareholders of the parent company reached ¥59,504,250,787.19, up from ¥45,519,861,860.32, indicating a growth of 30.6%[14] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥4,945,318,580.23, compared to ¥4,548,870,345.14 in 2024, reflecting an increase of 8.7%[16] Investment Activities - The cash outflow from investment activities was ¥1,714,462,484.69, compared to ¥2,124,667,512.24 in the previous year, showing a decrease in investment spending[20] - The company received cash from investment of ¥151,000,000.00, down from ¥200,000,000.00 in the previous year, indicating a decline in cash recovery from investments[20]